

McCormick et al
U.S. Serial No. 10/067,790
Page 6 of 6

REMARKS/ARGUMENTS

In response to the Restriction Requirement mailed February 24, 2005, Applicants elect group III, claims 51-53 with traverse. As for the election of species requirement, this is moot in view of the election. Should an election of a cytokine still be required, applicants elect GM-CSF. If the examiner requires election of a cytokine listed in original claim 39 (now canceled), applicants elect interferon-gamma.


Applicants have canceled non-elected claims 1-50 amended claims 51 and 53, added new claims 54-68 and present the following remarks. Claims 51-68 are pending.

Because the elected group were multiply dependant claims, language from earlier non-elected claims was incorporated into these claims and new claims added to avoid the need to be dependent on non-elected claims. All of the pending claims relate to specific novel methods for producing a composition. An action on the merits of these claims is respectfully requested.

If needed, applicants petition for sufficient extension of time for consideration of this paper.

The commissioner hereby is authorized to charge payment of any fees, including extension of time fees, under 37 CFR § 1.17, which may become due in connection with the instant application or credit any overpayment to Deposit Account No.500933.

Respectfully submitted,



John E. Tarcza
Reg. No. 33,638

Date: March 22, 2005

John E. Tarcza
Intellectual Property Advisor
Large Scale Biology Corporation
3333 Vaca Valley Parkway, Suite 1000
Vacaville, CA 95688
301-371-7740 tel.
301-371-7745 Fax.
E-MAIL john.tarcza@lsbc.com